rhodamine 123 has been researched along with trametinib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Jiang, QW; Li, Y; Mei, XL; Qin, WM; Qiu, JG; Shi, Z; Wei, MN; Xue, YQ; Yang, Y; Zhang, WJ; Zhang, YJ; Zhao, JM; Zheng, DW | 1 |
1 other study(ies) available for rhodamine 123 and trametinib
| Article | Year |
|---|---|
Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Moths; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pyridones; Pyrimidinones; Rhodamine 123; Vincristine; Xenograft Model Antitumor Assays | 2015 |